Sugi Predict

Sugi Predict / Compounds / SCHEMBL6370976

SCHEMBL6370976

SCHEMBL6370976

O=c1c(Br)c(NCc2ccccc2Cl)cnn1-c1c(Cl)cccc1Cl

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 11/20 0.78
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ BRD4 O60885 1/20 0.44
▸ KAT2B Q92831 1/20 0.44
▸ GRM2 Q14416 1/20 0.43
▸ IDE P14735 1/20 0.42
▸ POLB P06746 2/20 0.41
▸ BLM P54132 1/20 0.41
▸ GPR35 Q9HC97 1/20 0.41
▸ HDAC3 O15379 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6370767 0.91 MAPK14 (0.72) MAPK14SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL6348612 0.88 MAPK14 (1.00) MAPK14SMN1; SMN2RAB9ABRD4KAT2B
SCHEMBL6371718 0.82 MAPK14 (0.81) MAPK14SMN1; SMN2RAB9AKMT2ABRD4
SCHEMBL6376415 0.82 MAPK14 (1.00) MAPK14SMN1; SMN2RAB9AALDH1A1BRD4
SCHEMBL6371398 0.82 MAPK14 (0.73) MAPK14SMN1; SMN2RAB9AMAPT
SCHEMBL6370862 0.81 MAPK14 (1.00) MAPK14SMN1; SMN2RAB9AKMT2AMAPT
SCHEMBL6376389 0.79 MAPK14 (0.68) MAPK14SMN1; SMN2RAB9ANPSR1ALDH1A1
SCHEMBL6370469 0.78 MAPK14 (0.67) MAPK14SMN1; SMN2RAB9AMAPT
SCHEMBL6232218 0.77 MAPK14 (0.71) MAPK14SMN1; SMN2RAB9ABRD4KAT2B
SCHEMBL6370511 0.74 NPC1 (0.58) MAPK14SMN1; SMN2RAB9ANPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256122-A1 Substituted pyridazinones PHARMACIA CORPORATION 2005-11-17 — — US claimed
US-20050020594-A1 Substituted pyridazinones PHARMACIA CORPORATION 2005-01-27 — — US claimed
US-20040142932-A1 Substituted pyridazinones PHARMACIA CORPORATION 2004-07-22 — — US claimed
US-20050256122-A1 Substituted pyridazinones PHARMACIA CORPORATION 2005-11-17 — — US disclosed
US-20050020594-A1 Substituted pyridazinones PHARMACIA CORPORATION 2005-01-27 — — US disclosed
US-20040142932-A1 Substituted pyridazinones PHARMACIA CORPORATION 2004-07-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142932-A1 Substituted pyridazinones MAP4K2, MAPK6, MAP3K6 MAPK14 29/4885SMN1; SMN2 1185/4885RAB9A 2668/4885
US-20050020594-A1 Substituted pyridazinones MAP4K2, MAPK6, MAP3K6 MAPK14 34/4885SMN1; SMN2 1153/4885RAB9A 2627/4885
US-20050256122-A1 Substituted pyridazinones MAP4K2, MAPK6, MAP3K6 MAPK14 34/4885SMN1; SMN2 1153/4885RAB9A 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.